Outlook Therapeutics OTLK
NASDAQ OTLK
$0.59 +0.02 (+3.51%)
At close: Oct 2, 2026 · 4:00 PM EDT

Outlook Therapeutics (OTLK) Gains from Sales and Divestitures (2018 - 2019)

Updated

Outlook Therapeutics (OTLK) reported Gains from Sales and Divestitures of -$50,926 for fiscal Q3 2019 (quarter ended Jun 30, 2019).

Analysis

Outlook Therapeutics (OTLK) Gains from Sales and Divestitures (2018 - 2019) Analysis & Trends

Over the twelve months ended Jun 30, 2019, Outlook Therapeutics' Gains from Sales and Divestitures came in at -$2.96 million; for FY2017 (ended Sep 30, 2017), it was -$61,867.

  • By fiscal year, Gains from Sales and Divestitures came in at -$13,647 in FY2016.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Outlook Therapeutics 80.68 Mn 44.93 Mn -8,265.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2019 -50,926.00
Mar 31, 2019 -561,735.00
Dec 31, 2018 -2.35 Mn
API Access

Outlook Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=OTLK&period=max&api_key=YOUR_API_KEY